



DermTech Presents on Translational Medicine to Revolutionize Dermatologic Care at the Biomarkers & Precision Medicine USA Congress

October 10, 2022

LA JOLLA, Calif.--(BUSINESS WIRE)--Oct. 10, 2022-- [DermTech](#), Inc. (NASDAQ: DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced its presentation at the [Biomarkers & Precision Medicine USA Congress](#), held from Oct. 3-4 in San Diego. The 6th annual event featured industry-leading speakers from the pharma, biotech and academic spaces, sharing new case studies, innovative data and industry outlooks.

Erica Montano, Ph.D., a [DermTech Stratum™](#) research scientist, presented on the translational medicine services of DermTech Stratum and its precision-based approach to dermatology. The presentation, titled "Translational Research to Revolutionize Dermatologic Care," emphasized the Company's proprietary Smart Sticker™ and platform technology, highlighting its capabilities, specializations and advantages.

By non-invasively capturing genomic and proteomic material in the epidermis, DermTech's Smart Sticker and platform technology leverage skin gene and protein expression profiles in a clinical research setting to deliver accurate, objective and useful information; identify biomarkers that may be useful in stratifying a disease of interest or disease subgroup; and determine patient response to a selected target therapeutic. Additionally, the integration and implementation of the Smart Sticker in clinical trials improves patient enrollment in research studies and thus, data collection, as it is typically observed that less than 20% of eligible subjects volunteer for surgical skin biopsy collection due to its invasive nature.

Dr. Montano's presentation demonstrated the Smart Sticker's ability to identify potential atopic dermatitis (AD) and psoriasis subgroups, which optimizes clinical trial enrollment and diagnostic accuracy, and improves patient outcomes. She concluded with a focus on how this technology is poised to potentially revolutionize research in dermatology. A recording of her full presentation is available [here](#).

"I am pleased for the opportunity to present on behalf of DermTech Stratum at the 6th Annual Biomarkers & Precision Medicine USA Congress, sharing our translational medicine services that may revolutionize dermatologic care and research and development through precision and personalization," said Dr. Montano. "By leveraging genomic markers for precision medicine and clinical research, we can better aid in accurate diagnoses and predict and track responses to therapeutic intervention, ultimately improving patient care."

Dr. Montano is a highly experienced research scientist with a specialization in biomarker discovery. She holds a doctorate in biomedical science and translational medicine from Cedars Sinai Medical Center. While there, her research focused on understanding the immune defects underlying the pathology of lupus and identified novel metabolic differences in lupus patient immune cells, which contributed to genetic reprogramming and enhanced inflammation.

For additional information about DermTech Stratum, visit <https://dermtechstratum.com/>.

About DermTech

DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by its non-invasive skin genomics platform. DermTech's mission is to improve the lives of millions by providing non-invasive precision dermatology solutions that enable individualized care. DermTech provides genomic analysis of skin samples collected non-invasively using our Smart Stickers™. DermTech markets and develops products that facilitate the early detection of skin cancers and is developing products that assess inflammatory diseases and customize drug treatments. For additional information, please visit [DermTech](#).

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "outlook," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations and evaluations with respect to: the performance, patient benefits, cost-effectiveness, commercialization and adoption of DermTech's products and the market opportunity for these products, DermTech's positioning and potential revenue growth, financial outlook and future financial performance, ability to maintain or improve its operating efficiency, implications and interpretations of any study results, expectations regarding reimbursement or cash collection patterns from Medicare from commercial payors and related billing practices or number of covered lives, and DermTech's ability to expand its product offerings and develop pipeline products. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech's ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech's tests; (4) the reimbursement of DermTech's tests by Medicare and commercial payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech's products; (6) DermTech's ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech's products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in the "Risk Factors" section of the most recent Annual Report on Form 10-K filed by DermTech with the Securities and Exchange Commission (the "SEC"), and other documents filed or to be filed by DermTech with the SEC, including subsequently filed reports. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20221010005541/en/): <https://www.businesswire.com/news/home/20221010005541/en/>

Steve Kunszabo
DermTech
(858) 291-1647
steve.kunszabo@dermtech.com

Source: DermTech, Inc.